NasdaqGS:KRYSBiotechs
Krystal Biotech (KRYS): Assessing Valuation After Positive KB707 Lung Cancer Trial and Strategic Clinical Pivot
Krystal Biotech (KRYS) has just shifted its clinical development strategy in a way that is sure to catch the eye of investors weighing what to do next. The company reported encouraging results from its inhaled KB707 trial in non-small cell lung cancer, delivering a 36% objective response rate in a tough patient group. Following this data, Krystal secured a key FDA End of Phase 2 meeting, aimed at accelerating a registration path for this therapy. At the same time, they are pausing the...